Print this page
Email a friend
Was this information helpful?
(0 votes)What do you think? Click "thumbs up" or "thumbs down" to vote!
If you have more to say, post a comment below!
A different study of diabetes drugs showed that Avandia and its competitor Actos are neither better nor worse than injected insulin in preventing death from cardiovascular complications of type 2 diabetes. The study was partially funded by the National Institutes of Health and lasted five years. During that time, 11.8 % of those on Actos or Avandia died, compared to 12.1 % of those on insulin. There is no statistical difference between these treatments. The investigators were disappointed that there was no clear benefit from the newer and more expensive diabetes drugs.
[American Diabetes Association scientific meeting, June, 2009]
Avandia and Actos appear to be accepted RX's to be used by Type 2 Diabetes patients. Actos is twice as expensive as Avandia (approx $600/90 tablets vs $300). Is there some reason the less expensive one should not be used?